DEBRA PALAZZI to Antifungal Agents
This is a "connection" page, showing publications DEBRA PALAZZI has written about Antifungal Agents.
Connection Strength
0.980
-
Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study. Pediatr Infect Dis J. 2014 Dec; 33(12):1294-6.
Score: 0.373
-
Risk factors of amphotericin B toxicty in the nonneonatal pediatric population. Pediatr Infect Dis J. 2012 Sep; 31(9):910-4.
Score: 0.319
-
Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network. J Pediatric Infect Dis Soc. 2024 Dec 30; 13(12):633-638.
Score: 0.188
-
Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal Network. J Pediatric Infect Dis Soc. 2023 Sep 27; 12(9):487-495.
Score: 0.043
-
An evidence-based, risk-adapted algorithm for antifungal prophylaxis reduces risk for invasive mold infections in children with hematologic malignancies. Pediatr Blood Cancer. 2021 12; 68(12):e29228.
Score: 0.037
-
Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J. 2012 Dec; 31(12):1252-7.
Score: 0.020